241 related articles for article (PubMed ID: 27764180)
1. Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration.
Chung JK; Brown E; Crooker B; Palmieri KJ; McCauley TG
PLoS One; 2016; 11(10):e0164765. PubMed ID: 27764180
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
Xie H; Chung JK; Mascelli MA; McCauley TG
PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
[TBL] [Abstract][Full Text] [Related]
3. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder.
Calias P; Papisov M; Pan J; Savioli N; Belov V; Huang Y; Lotterhand J; Alessandrini M; Liu N; Fischman AJ; Powell JL; Heartlein MW
PLoS One; 2012; 7(1):e30341. PubMed ID: 22279584
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys.
Felice BR; Wright TL; Boyd RB; Butt MT; Pfeifer RW; Pan J; Ruiz JA; Heartlein MW; Calias P
Toxicol Pathol; 2011 Aug; 39(5):879-92. PubMed ID: 21628718
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
Muenzer J; Hendriksz CJ; Fan Z; Vijayaraghavan S; Perry V; Santra S; Solanki GA; Mascelli MA; Pan L; Wang N; Sciarappa K; Barbier AJ
Genet Med; 2016 Jan; 18(1):73-81. PubMed ID: 25834948
[TBL] [Abstract][Full Text] [Related]
7. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA; Kimura A
Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288
[TBL] [Abstract][Full Text] [Related]
11. Idursulfase in Hunter syndrome treatment.
Zareba G
Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
[TBL] [Abstract][Full Text] [Related]
13. Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
Muenzer J; Burton BK; Harmatz P; GutiƩrrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
Mol Genet Metab; 2022; 137(1-2):92-103. PubMed ID: 35961250
[TBL] [Abstract][Full Text] [Related]
14. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
[TBL] [Abstract][Full Text] [Related]
15. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
[TBL] [Abstract][Full Text] [Related]
17. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
[TBL] [Abstract][Full Text] [Related]
18. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
Muenzer J; Burton BK; Harmatz P; GutiƩrrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
Mol Genet Metab; 2022; 137(1-2):127-139. PubMed ID: 36027721
[TBL] [Abstract][Full Text] [Related]
20. Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II.
Muenzer J; Vijayaraghavan S; Stein M; Kearney S; Wu Y; Alexanderian D
Genet Med; 2022 Jul; 24(7):1437-1448. PubMed ID: 35588317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]